The utility of drugs that regulate epigenetic patterns in cells are gaining traction in oncology in part due to reported cytostatic effect on tumor cells. While much attention is on tumor cells, little is known about their effects on immune cells that are recruited to the tumor microenvironment. This issue is of particular importance when considering the increasing appeal of immunotherapeutic drugs which show promising results in cancer patients where other therapies have failed. Such therapeutic outcomes are attributed to re-invigoration of effector components of immune cells. Thus agents which have the potential to promote immune cell function while dampening inhibitory mechanisms within the tumor microenvironment are predicted to promote therapeutic benefits. In this regard, we have found that an inhibitor targeting select histone deacetylases, and an inhibitor of the BET family of bromodomain protein exhibit remarkable immune-modulating effects that support improved immune function. The current proposal will build on these findings to understand how these drugs work, and how these unique properties can be leveraged for treatment of non-small cell lung cancer using rational combinatorial drug regimen. Thus, the following aims are proposed: (1) To understand the effect of ACY241 and JQ1 on global gene networks and epigenetic footprints in tumor- associated immune cell subsets. (2) To evaluate the therapeutic potential of ACY241 and JQ1 as partner agents in combinatorial therapy for non-small cell lung cancer (NSCLC) using genetically engineered mouse model (GEMM). (3) To evaluate the effects of novel drug combinations tested in GEMM on ex-vivo propagated patient tumor cultures as a gauge for clinical applicability.

Public Health Relevance

The efficacy of immunotherapeutic drugs in some cancer patients shows that the immune system's ability to fight cancer can be unleashed with the right drugs. This proposal builds on our observations that certain drugs that indirectly regulate gene expression caused changes in immune cells surrounding lung cancer in a manner that favored their improved function. We will build on this by investigating how these drugs might promote this effect and evaluate their application for the treatment of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Career Transition Award (K22)
Project #
5K22CA222669-02
Application #
9763498
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Schwartz, Elena Ivan
Project Start
2018-08-14
Project End
2021-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612